OP Asset Management Ltd Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN

OP Asset Management Ltd bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 1st quarter, Holdings Channel reports. The fund bought 14,139 shares of the biopharmaceutical company’s stock, valued at approximately $10,924,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after acquiring an additional 26,884 shares during the last quarter. Dodge & Cox raised its position in shares of Regeneron Pharmaceuticals by 1.0% in the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after acquiring an additional 45,513 shares during the period. Franklin Resources Inc. boosted its stake in Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after acquiring an additional 106,861 shares during the last quarter. Nuveen LLC boosted its stake in Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after acquiring an additional 835,240 shares during the last quarter. Finally, Capital World Investors grew its holdings in Regeneron Pharmaceuticals by 1.6% during the third quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock valued at $1,123,609,000 after purchasing an additional 32,348 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on REGN shares. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Leerink Partners reissued a “market perform” rating and issued a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating for the company in a research report on Monday, May 18th. JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $792.65.

Regeneron Pharmaceuticals Stock Down 0.5%

Regeneron Pharmaceuticals stock opened at $620.14 on Friday. The company has a 50 day moving average of $665.93 and a 200-day moving average of $729.12. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a twelve month low of $514.79 and a twelve month high of $821.11. The stock has a market capitalization of $65.56 billion, a PE ratio of 15.11, a price-to-earnings-growth ratio of 1.37 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s quarterly revenue was up 19.0% on a year-over-year basis. During the same period last year, the business posted $8.22 earnings per share. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.